Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 4;9(10):e002505. doi: 10.1136/jitc-2021-002505

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Baseline tissue parameters in the OPERA trial illustrating accumulation of CXCL12 in the CRC liver metastases and the immune alteration in the patient cohort. (A) Concentration of CXCL12 in tumor lysate of CRC primary tumor lysates and their corresponding liver metastases. (B) Concentration of CXCL12 in the primary tumors compared with their adjacent stroma and corresponding sera. (C) CD3⁺ T cell density in liver metastases in the OPERA trial and in a reference cohort.CRC, colorectal cancer; CXCL12, chemokine (C-X-C motif) ligand 12.